Realgar-induced KRAS mutation lung cancer cell death via KRAS/Raf/MAPK mediates ferroptosis

KRAS is a biomarker for non-small cell lung cancer-targeted therapy, but there is currently no effective KRAS-targeting medication. Realgar is an impelling anti-cancer drug, however its significance in KRAS mutant lung cancer is uncertain. According to our findings, the IC(50) of H23 (KRAS mutant) c...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiaofeng, Hai, Yang, Dong, Jinqu, Xu, Lan, Hou, Wenqian, Su, Jing, Ren, Weiyu, Liu, Dongling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635866/
https://www.ncbi.nlm.nih.gov/pubmed/36321791
http://dx.doi.org/10.3892/ijo.2022.5447

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635866/
https://www.ncbi.nlm.nih.gov/pubmed/36321791
http://dx.doi.org/10.3892/ijo.2022.5447

Ejemplares similares